logo
Peptides: performance-boosting, anti-ageing drugs or dangerous snake oil?

Peptides: performance-boosting, anti-ageing drugs or dangerous snake oil?

Indian Express3 days ago
By Adam Taylor
For a growing number of middle-aged men, ageing no longer means surrendering to sagging skin, sore joints or slowing metabolism. Instead, it's becoming a science experiment. The new frontier? Injectable peptides – experimental compounds that promise rapid recovery, fat loss and muscle gains with the ease of a twice-daily to weekly jab.
Once confined to elite labs and obscure bodybuilding forums, these amino acid chains are now flooding wellness spaces, social media feeds and online marketplaces. Although they are marketed as 'next-generation biohacks' and 'research chemicals', many peptides are not approved for human use and lack basic clinical testing.
Still, their popularity is growing – fuelled by testimonials, influencer hype and the seductive promise of turning back time.
But beneath the surface of glossy marketing and fitness fantasies lies a far more sobering truth: many of these substances operate in a medical grey zone, with unknown long-term risks, questionable manufacturing standards, and in some cases, life-threatening side-effects
Peptides aren't entirely new to medicine. The first peptide drug – insulin – was isolated in 1921 and became commercially available in 1923. Today over 100 peptide medications are approved, including semaglutide – better known as Ozempic and Wegovy.
But the compounds now circulating in fitness communities represent a very different category. They're experimental substances that have shown promise in animal studies but have never undergone proper human trials.
One such compound, first discovered in human gastric juice, that is attracting lots of attention is BPC-157. Early animal studies suggest it may help repair damaged tissue throughout the body.
Researchers tested it on mice, rats, rabbits and dogs without finding serious side-effects. The compound appears to support healing of the tendons, teeth and digestive organs, including the stomach, intestines, liver and pancreas.
Scientists don't yet fully understand how BPC-157 works, but animal studies suggest it triggers several biological processes essential for healing. The compound appears to help cells move to damaged areas and encourages the growth of new blood vessels, bringing nutrients and oxygen to tissues in need of repair.
Another compound gaining attention is TB500. It is a synthetic version of thymosin beta-4, a naturally occurring protein fragment that plays an important role in repairing and regenerating damaged cells and tissues.
It also helps protect cells from further harm by reducing inflammation and defending against microbes. The combination of BPC-157 and TB500 has earned the nickname 'the Wolverine stack', named after the Marvel superhero famous for his rapid healing.
Then there's IGF-1 LR3, a modified version of a natural protein (IGF-1) linked to muscle growth. This synthetic compound was shown to increase muscle mass by 2.5 times in animal studies, though it has never been studied in humans.
The limited human research that does exist for these compounds offers inconclusive results. For example, a study showed that over 90% of patients experienced reduced knee pain after BPC-157 injections. However, the study had no control group and several methodological issues, so the results should be viewed with caution.
Even though the early results seem exciting, these experimental compounds can be dangerous. Making them involves special chemicals called coupling agents, which can trigger serious allergic reactions, including anaphylaxis – a life-threatening condition.
The health consequences extend well beyond allergic reactions. Long-term injection of performance-enhancing substances can lead to heart failure that can occur rapidly with little warning, as documented in recent medical case studies of young bodybuilders.
Injection-related injuries pose another significant threat. 'Compartment syndrome' can develop at injection sites in leg muscles, causing numbness, blood clots and muscle spasms that result in permanent loss of function.
In severe cases, skin and underlying tissue can suffer necrosis (tissue death), requiring antibiotics or surgery to treat. More alarming still are reports of users contracting HIV, hepatitis B and C, and serious eye infections from contaminated injections.
These compounds don't just target muscles – they affect the entire body in ways scientists are only beginning to understand. Some interfere with natural insulin production, while others activate biological pathways that healthy cells use for growth and repair.
The concern is that these same pathways are exploited by cancer cells. The VEGF pathway, which promotes blood vessel growth, is active in about half of all human cancers, including melanoma and ovarian cancer. Laboratory studies suggest that thymosin beta-4 may play a role in helping colorectal and pancreatic cancers spread.
While there's no direct evidence linking compounds like BPC-157 or TB500 to cancer, researchers emphasise that the long-term effects remain unknown because these substances have never undergone proper human trials. The World Anti-Doping Agency has banned these compounds, noting they lack approval from any health regulatory authority and are intended only as research tools.
Yet their use appears to be spreading rapidly. A 2014 study found that 8.2% of gym members used performance-enhancing drugs. By 2024, a comprehensive review suggested the figure could be as high as 29%. Perhaps most concerning: only 38% of users recognised the health risks involved.
These experimental compounds represent a dangerous gamble with long-term health. Unlike approved drugs, they haven't undergone the rigorous testing required to understand their safety profile in humans. While they may promise enhanced performance and healing, they deliver it at a cost that users may not fully understand until it's too late.
The appeal is understandable – who wouldn't want faster healing and better muscle tone? But the reality is these substances remain experimental for good reason. Until proper human trials are conducted, users are essentially volunteering as test subjects in an uncontrolled experiment with their own bodies.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Economic Times

time3 hours ago

  • Economic Times

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play

Mint

time3 hours ago

  • Mint

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play

Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.

66-year-old woman who dropped 18 kg shares 8 foods that made her ‘fat loss 10x easier': Berries, avocado, nuts and more
66-year-old woman who dropped 18 kg shares 8 foods that made her ‘fat loss 10x easier': Berries, avocado, nuts and more

Hindustan Times

time8 hours ago

  • Hindustan Times

66-year-old woman who dropped 18 kg shares 8 foods that made her ‘fat loss 10x easier': Berries, avocado, nuts and more

Ilene, a 66-year-old Instagram user, achieved an incredible weight transformation, shedding 18 kilos. What makes her journey truly inspiring is not just the weight she lost, but the fact that she accomplished it in her 60s. Ilene regularly shares glimpses of her experience, along with valuable lessons, diet tips, and lifestyle habits to help others on their own fitness journeys. Add these foods to your diet to make fat loss easier.(Shutterstock) Ilene, on June 12, shared an Instagram post to help her followers add the right kind of food items to their weight loss diet. 'Nobody told me this before I lost 40 lbs, so I'm telling you now. These foods mimic Ozempic and make fat loss 10x easier,' she wrote. Also read | Losing weight after 60: Healthy diet plan and exercise tips for seniors 1. Greek yogurt Why it helps: High-protein + fermented = big GLP-1 bump, steadier blood sugar, longer fullness. How to eat it: ¾ cup 2 % Greek yogurt + ½ cup berries + ½ scoop protein = 35 g protein breakfast or post-lift snack. 2. Sweet potatoes (especially cooled and reheated) Why it helps: Fiber + resistant starch ⟶ slower gastric emptying, steadier insulin, higher GLP-1 release. How to eat it: Roast, chill overnight, cube into salads or reheat with cinnamon and a dollop of Greek yogurt. 3. Berries Why they help: Polyphenols + fiber blunt glucose spikes and trigger satiety signals. How to eat them: Top oats, blend into protein shakes, or freeze-dry for a crunchy topping. 4. Eggs Why they help: Protein, healthy fats, and choline keep hunger hormones low and GLP-1 higher for hours. How to eat them: 2 whole eggs + ½ cup egg whites scramble → 30 g protein, add spinach for extra fiber. 5. Oats Why they help: β-glucan fiber thickens in your gut, slowing digestion and boosting GLP-1. Also read | How to lose weight after 50? Dietician shares simple steps to shed pounds and stay healthy How to eat them: ½ cup oats + water, stir in 1 scoop whey and 1 tbsp chia; microwave; top with berries ➜ protein + fiber powerhouse. 6. High-fiber veggies (broccoli, brussels sprouts, kale) Why they help: Insoluble + soluble fiber = slower carb absorption, more GLP-1, better gut health. How to eat them: Roast a sheet pan in olive oil & garlic; add to every plate (aim for 3 colors each meal). 7. Beans and lentils Why they help: Plant protein + resistant starch + fiber triple-team satiety hormones. How to eat them: ½ cup lentils in quinoa bowls or blend black beans into turkey-chili. 8. Avocado and nuts Why they help: Healthy monounsaturated fats delay gastric emptying and sustain GLP-1 signaling. How to eat them: ¼ avocado on Ezekiel toast or 10–12 almonds alongside Greek yogurt. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store